These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 23647808)
21. A case of hepatic metastasis from gastric GIST successfully resected following neoadjuvant targeted therapy. Onoe S; Sakamoto Y Jpn J Clin Oncol; 2011 Apr; 41(4):590. PubMed ID: 21447695 [No Abstract] [Full Text] [Related]
22. [Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk]. Li SX; Li ZY; Zhang LH; Bu ZD; Wu AW; Wu XJ; Zong XL; Shan F; Ji X; Ji JF Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):226-9. PubMed ID: 23536340 [TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573 [TBL] [Abstract][Full Text] [Related]
24. Management of liver metastases of gastrointestinal stromal tumors (GIST). Vassos N; Agaimy A; Hohenberger W; Croner RS Ann Hepatol; 2015; 14(4):531-9. PubMed ID: 26019040 [TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587 [TBL] [Abstract][Full Text] [Related]
26. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320 [TBL] [Abstract][Full Text] [Related]
27. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib. Wilkinson MJ; Fitzgerald JE; Strauss DC; Hayes AJ; Thomas JM; Messiou C; Fisher C; Benson C; Tekkis PP; Judson I Br J Surg; 2015 Jul; 102(8):965-71. PubMed ID: 25970743 [TBL] [Abstract][Full Text] [Related]
29. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234 [TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors. Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T Digestion; 2013; 87(1):47-52. PubMed ID: 23343969 [TBL] [Abstract][Full Text] [Related]
31. Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification. Cananzi FC; Judson I; Lorenzi B; Benson C; Mudan S Eur J Surg Oncol; 2013 Nov; 39(11):1171-8. PubMed ID: 24063969 [TBL] [Abstract][Full Text] [Related]
32. A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors. Hakimé A; Le Cesne A; Deschamps F; Farouil G; Boudabous S; Aupérin A; Domont J; Debaere T Cardiovasc Intervent Radiol; 2014 Feb; 37(1):132-9. PubMed ID: 23589213 [TBL] [Abstract][Full Text] [Related]
34. Surgical management of gastrointestinal stromal tumours: a single centre experience during the past 17 years. De Vogelaere K; Van De Winkel N; Aerts M; Haentjens P; Spitali C; Van Loo I; Delvaux G Acta Chir Belg; 2014; 114(3):167-73. PubMed ID: 25102705 [TBL] [Abstract][Full Text] [Related]
35. Surgical management of rectal gastrointestinal stromal tumors. Tielen R; Verhoef C; van Coevorden F; Reyners AK; van der Graaf WT; Bonenkamp JJ; van Etten B; de Wilt JH J Surg Oncol; 2013 Mar; 107(4):320-3. PubMed ID: 22806955 [TBL] [Abstract][Full Text] [Related]
36. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. Machlenkin S; Pinsk I; Tulchinsky H; Ziv Y; Sayfan J; Duek D; Rabau M; Walfisch S Colorectal Dis; 2011 Oct; 13(10):1110-5. PubMed ID: 21040362 [TBL] [Abstract][Full Text] [Related]
37. [A case report of two-term surgery for focal progression of a huge liver metastasis and peritoneal dissemination from gastrointestinal stromal tumor during imatinib mesylate treatment]. Toyokawa T; Teraoka H; Kitayama K; Nomura S; Kanehara I; Nishino H Gan To Kagaku Ryoho; 2014 Mar; 41(3):373-7. PubMed ID: 24743287 [TBL] [Abstract][Full Text] [Related]
38. [Current aspects of treatment in gastrointestinal stromal tumors (GIST)]. Láng I; Hitre E Orv Hetil; 2005 May; 146(18 Suppl 1):935-41. PubMed ID: 15921308 [TBL] [Abstract][Full Text] [Related]
39. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. DeMatteo RP; Maki RG; Singer S; Gonen M; Brennan MF; Antonescu CR Ann Surg; 2007 Mar; 245(3):347-52. PubMed ID: 17435539 [TBL] [Abstract][Full Text] [Related]
40. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Bauer S; Hartmann JT; de Wit M; Lang H; Grabellus F; Antoch G; Niebel W; Erhard J; Ebeling P; Zeth M; Taeger G; Seeber S; Flasshove M; Schütte J Int J Cancer; 2005 Nov; 117(2):316-25. PubMed ID: 15900603 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]